Welcome to our dedicated page for Insmed news (Ticker: INSM), a resource for investors and traders seeking the latest updates and insights on Insmed stock.
Insmed Incorporated develops and commercializes biopharmaceutical therapies for serious diseases, with a commercial respiratory portfolio that includes ARIKAYCE® (amikacin liposome inhalation suspension) and BRINSUPRI® (brensocatib). Its pipeline spans pulmonary, inflammatory, immunology and rare-disease programs, including TPIP and INS1148, alongside early research in gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining and synthetic rescue.
Recurring company news covers product revenue trends, regulatory authorizations and label-development activity for ARIKAYCE and BRINSUPRI, clinical data in MAC lung disease, non-cystic fibrosis bronchiectasis and inflammatory conditions, and presentations at medical and investor conferences. Updates also include portfolio-prioritization decisions, financial results, employee equity inducement grants and other governance-related announcements.
Insmed Incorporated (Nasdaq: INSM) announced on July 6, 2020, the granting of inducement awards to 11 new employees. These awards, approved by Insmed's Compensation Committee, consist of options to purchase a total of 66,400 shares of common stock at an exercise price of $29.19 per share, the closing price on the date of grant (July 1, 2020). The options have a ten-year term and a four-year vesting schedule. Insmed is focused on transforming the lives of patients with serious and rare diseases, with ARIKAYCE® as its first commercial product for treating MAC lung disease.
Insmed announced final results from the Phase 2 WILLOW study of brensocatib in patients with non-cystic fibrosis bronchiectasis (NCFBE). The study met its primary endpoint, showing significant prolongation of time to first pulmonary exacerbation versus placebo (p=0.027 for 10 mg; p=0.044 for 25 mg). Notably, the 10 mg group had a 42% reduction in exacerbation risk. The treatment was well-tolerated, with the most common adverse events being cough and headache. Following these results, Insmed plans to initiate a Phase 3 program for brensocatib in bronchiectasis in the second half of 2020.